Precision BioSciences DTIL 深 滬
等待開盤 11-04 09:30:00 美东时间
6.97
+0.020
+0.29%
華盛通- 最 高7.20
- 今 開6.95
- 成交量 14.48万股
- 最 低 6.64
- 昨 收 6.95
- 總市值 1.92亿
- 52周最高 9.62
- 市盈率 靜 --
- 換手率 0.52%
- 52周最低 3.53
- 委 比 12.36%
- 總股本 2760.16万
- 歷史最高 710.10
- 量 比 0.91
- 振 幅 8.06%
- 歷史最低 3.53
- 每 手 1
- 風險率 1.43%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多UPDATE: Precision BioSciences Q3 Adj. EPS $(0.74) Beats $(0.85) Estimate
Precision BioSciences (NASDAQ:DTIL) reported quarterly losses of $(0.74) per share which beat the analyst consensus estimate of $(0.85) by 12.94 percent. This is a 59.78 percent increase over losses of $(1.84) per share from the same period last year.
今天 07:03
Precision BioSciences收涨10.01%，成交额136.12万美元
10月29日，Precision BioSciences（DTIL）收涨10.01%，报7.47美元，成交额136.12万美元，市值2.06亿美元。 行情数据...
10-29 06:37
Precision BioSciences收涨5.98%，成交额139.98万美元
10月21日，Precision BioSciences（DTIL）收涨5.98%，报6.56美元，成交额139.98万美元，市值1.81亿美元。 行情数据 ...
10-21 06:46
Precision BioSciences收跌6.48%，成交额177.61万美元
10月20-22日上海黄浦江畔，2026可持续全球领导者大会再度来袭。诺奖、图灵奖得主现场讲述科技未来与趋势，更有“解救”焦虑、内卷时代的网红教授——麦克法兰与...
10-17 06:52
iECURE Says Updated OTC-HOPE Low-Dose Data Showed 74% Reduction In Annualized Hyperammonemic Crises, 57% Reduction In Hyperammonemic Events; Completes Phase 1/2 Dosing Across All Three Cohorts
iECURE, a private clinical-stage genome editing company, reported preliminary safety observations from all nine participants dosed with ECUR-506 across the low-, intermediate- and high-dose cohorts, saying the therapy was generally well tolerated as of the July 28, 2026 data cutoff, with no unexpect...
08-27 20:07
Precision BioSciences Begins First DMD Gene-Editing Trial
The latest update is out from Precision BioSciences ( ($DTIL) ). On August 24, ...
08-24 19:49
iECURE Announces Updated Safety And Metabolic Control Data From Phase 1/2 Trial Of ECUR-506 In Neonatal-Onset OTC Deficiency To Be Presented August 27 At SSIEM Symposium
iECURE has licensed the ARCUS® nuclease from Precision BioSciences for four gene insertion programs including OTC, CTLN1 and PKU.
08-20 20:03
Precision BioSciences调整高管团队，助力临床项目冲刺关键里程碑
临床阶段基因编辑公司Precision BioSciences （Nasdaq： DTIL） 今日宣布对其高级领导团队进行调整，旨在为核心项目的下一阶段临床...
07-27 21:53
Precision BioSciences Announces Key Executive Leadership Changes
Precision BioSciences ( ($DTIL) ) has issued an announcement. On July 23, 2026,...
07-27 19:58
Precision BioSciences announces key management changes
Precision BioSciences (DTIL) announced changes to its senior leadership team as the gene-editing company prepares to advance its lead clinical programs. Alex Kelly will be promoted from CFO to the new...
07-27 19:18
